Literature DB >> 9515773

Enterovirus infections and enterovirus specific T-cell responses in infancy.

S Juhela1, H Hyöty, M Lönnrot, M Roivainen, O Simell, J Ilonen.   

Abstract

The development of enterovirus specific T-cell and antibody responses were examined in a cohort of 60 healthy infants at the ages of 3, 6, 9, and 12 months. By the age of 6 months, 68% of the infants had developed T-cell responses against enterovirus antigens by lymphocyte proliferation test, whereas only 30% had serological evidence of an enterovirus infection. By this age, only 7% of the infants had adenovirus specific T-cell responses and 3% had serologically verified adenovirus infection. Enterovirus specific T-cell responses correlated with the lack of enterovirus antibodies in cord blood and the number of sibs reflecting protection by maternal antibodies and the rate of exposures, respectively. T-cell responses cross-reacted between different enterovirus serotypes. The results show that enterovirus infections occur frequently in infancy and induce T-cell immunity. Cellular immunity may be a more sensitive indicator of neonatal enterovirus infections than antibodies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9515773     DOI: 10.1002/(sici)1096-9071(199803)54:3<226::aid-jmv14>3.0.co;2-f

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  17 in total

Review 1.  Immunisation and type 1 diabetes mellitus: is there a link?

Authors:  M Hiltunen; M Lönnrot; H Hyöty
Journal:  Drug Saf       Date:  1999-03       Impact factor: 5.606

Review 2.  Immunisation of premature infants.

Authors:  J Bonhoeffer; C-A Siegrist; P T Heath
Journal:  Arch Dis Child       Date:  2006-11       Impact factor: 3.791

3.  No evidence of abnormal regulation of antibody response to coxsackievirus B4 antigen in prediabetic children.

Authors:  L Heino; M Lönnrot; M Knip; A Kupila; S Erkkilä; A Toivonen; P Vähäsalo; J Ilonen; O Simell; H Hyöty
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

4.  Characterization of the enterovirus 71 P1 polyprotein expressed in Pichia pastor as a candidate vaccine.

Authors:  Xue Han; Xiao-ling Ying; Shi-li Zhou; Tao Han; Hao Huang; Qi Jin; Fan Yang; Qi-ying Sun; Xian-xun Sun
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  Comparison of enterovirus-specific cellular immunity in two populations of young children vaccinated with inactivated or live poliovirus vaccines.

Authors:  S Juhela; H Hyöty; R Uibo; S H Meriste; O Uibo; M Lönnrot; M Halminen; O Simell; J Ilonen
Journal:  Clin Exp Immunol       Date:  1999-07       Impact factor: 4.330

6.  The compatibility of inactivated-Enterovirus 71 vaccination with Coxsackievirus A16 and Poliovirus immunizations in humans and animals.

Authors:  Qunying Mao; Yiping Wang; Jie Shao; Zhifang Ying; Fan Gao; Xin Yao; Changgui Li; Qiang Ye; Miao Xu; Rongcheng Li; Fengcai Zhu; Zhenglun Liang
Journal:  Hum Vaccin Immunother       Date:  2015-02-25       Impact factor: 3.452

7.  Hand, foot and mouth disease: seroprevalence of Coxsackie A16 and Enterovirus 71 in Germany.

Authors:  Holger F Rabenau; Matthias Richter; Hans Wilhelm Doerr
Journal:  Med Microbiol Immunol       Date:  2009-11-26       Impact factor: 3.402

8.  Enterovirus infections as a risk factor for type I diabetes: virus analyses in a dietary intervention trial.

Authors:  K Sadeharju; A-M Hämäläinen; M Knip; M Lönnrot; P Koskela; S M Virtanen; J Ilonen; H K Akerblom; H Hyöty
Journal:  Clin Exp Immunol       Date:  2003-05       Impact factor: 4.330

9.  Immunity to avirulent enterovirus 71 and coxsackie A16 virus protects against enterovirus 71 infection in mice.

Authors:  Te-Chia Wu; Ya-Fang Wang; Yi-Ping Lee; Jen-Ren Wang; Ching-Chuan Liu; Shih-Min Wang; Huan-Yao Lei; Ih-Jen Su; Chun-Keung Yu
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

10.  Seroepidemiology of echovirus 30 in Korean children.

Authors:  Joo Young Lee; Yumi Seo; Ui Yoon Choi; Jong-Hyun Kim; Jin Han Kang
Journal:  World J Pediatr       Date:  2017-08-02       Impact factor: 2.764

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.